

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
 Disclaimers I-2
 Data Interpretation & Reporting Level I-2
 Quantitative Techniques & Analytics I-3
 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

Regenerative Medicine - the Past, the Present, & the Future II-1
 Another Revolution in the Making? II-2
 Conventional Chemical Medicine Vs Regenerative Medicine II-2
 The Need for Regenerative Medicine II-3
 Regenerative Medicine Throws in Several New Therapies II-3
 What's in Store? II-3
 Regenerative Medicine to Arrest Ageing II-3
 Thriving on an Aging World Population II-4
 Faster Healing Process II-4
 Regenerative Medicine to Overcome Donor Organs Shortage II-4
 Possible Scenarios II-5
 Stem Cell Research – Not Just Another Medical Advancement II-5
 Key Issues At Play II-6
 Market Potential II-6
 Regenerative Medicine in Bone and Joint Applications II-6
 US Corners a Lion's Share II-6
 Growth Drivers II-6
 Trends & Issues II-7
 Biomaterials Sought After in Regenerative Medicine II-7
 Upbeat Market for Cell-based Tissue Engineering II-7
 Progenitor Cell Therapy to Witness No Holds Barred Growth II-8
 Players Embrace Automation in Production Facilities II-8
 Contract Manufacturing, a Growing Sector II-9
 Investors Wary of Funding Regenerative Medicine II-9
 Regenerative Medicine Field Lags Behind due to Segregated Focus II-9
 Challenges to Be Encountered by Tissue Engineering Companies II-10
 Activity in the Field of Regenerative Medicine II-10

2. Product Overview II-12

Regenerative Medicine Advances in Four Phases II-12
 Human Substances II-12
 Tissue Engineering II-12
 Therapeutic Cloning II-12
 Nanotechnology-Driven Biomaterials II-12

Types of Regenerative Medicine II-12
 Type 1 – Regenerative Medicine II-13
 Human Proteins and Genes are Drugs in Regenerative Medicine II-13
 Type-2 Regenerative Medicine II-13
 Therapies Based on Human Cells and Tissues II-13
 Type-3 Regenerative Medicine II-15
 Based on Embryonic Stem Cells II-15
 The Opponents of the ESC Theory II-16
 Embryonic Stem Cells – Shortcomings II-16
 Type-4 Regenerative Medicine II-17
 Based on Novel Materials / Material Science Advancements II-17
 Overview of Major Regenerative Medicine Techniques II-18
 Natural Regenerative Proteins II-18
 Tissue Engineering Capable of Culturing Replacement Organs II-18
 All About Stem Cells II-19
 Adult Stem Cells II-19
 Adult Stem Cell Research Eludes Ethical Dispute II-19
 hESC – Highly Capable of Differentiating and Multiplying II-19
 Stem Cell Research in Development of Regenerative Medicine II-20
 Neural Stem Cell to Restore Memory Functioning II-20
 Pancreatic Islet Cells to Control Blood Sugar in Diabetics II-20
 Therapeutic Cloning to Cure Parkinson's II-21

3. Regulatory Environment II-22

Regulatory Norms Governing ES Cell Research II-22
 Milestones in the Human Embryonic Stem Cell Research: 2001 II-22
 Legality of ES Cell Use in Major Developed Nations II-22

4. Technological Innovations / Breakthroughs II-23

Celprogen Launches 11 Cancer Stem Cells II-23
 Biovest International Launches AutovaxID™ II-23
 Stelic Institute Announces New Treatment Method for Acute Liver Failure II-23
 TissueGene Initiates Phase 1 Clinical Trials for TG-C II-24
 ISTO Announces FDA's IND Approval for Neocartilage Graft II-24
 Cook Biotech Introduces Surgisis® AFP™ Anal Fistula Plug II-24
 Korean Scientists Make a Major Breakthrough in Stem Cell Lines II-24
 Japanese Researchers Regenerate Jaw Bone II-25
 Geron Researchers Differentiate Hepatocytes from hESCs II-25
 Geron Demonstrates Potential of hESCs in Treatment of Parkinson's disease II-25
 Geron Researches Cardiomyocytes for Heart Disease II-26
 Endovasc Announces New Findings at Texas Heart Institute Research II-26

CONTENTS

Geron and Celera Genomics Complete Characterization of Active Genes in hESCs	II-26	Curis Collaborates with Wyeth Pharmaceuticals	II-37
Rockefeller University Develops Solution for Maintaining Pluripotency in hESCs	II-27	co.don Strikes a Deal with Bioengi Ltd.....	II-37
5. Recent Industry Activity.....	II-28	StemCells Licenses Stem Cell Technology to ReNeuron	II-37
Cytori and Green Hospital Supply Ink Strategic Equity Deal.....	II-28	Osiris Receives FDA Approval to Commence Stem Cell Trial for Knee Repair	II-38
RNL Bio Establishes Research Unit at Newcastle University.....	II-28	Geron Corporation and BRC Establish TA Therapeutics Limited	II-38
Tengion Begins Third Phase II Clinical Trial of Neo-Bladder Augment™.....	II-28	Celmed BioSciences Pockets NewBiotics.....	II-38
Organogenesis Signs MoU with NTEC.....	II-28	Celmed BioSciences Collaborates with Gambro BCT.....	II-38
BioTime Establishes New Stem Cell Division	II-29	Ortec Collaborates with ESI.....	II-38
Integra Life Sciences Acquires IsoTis, Inc.....	II-29	BMPI in Alliance with Luitpold Pharmaceuticals	II-39
NovaThera and Gamida Join Hands for Developing Cell Therapeutics for Lung Regeneration	II-29	BioVest International Enters into a Supply Agreement with Bioventix	II-39
Tigenix Teams Up With Fidea to Develop Biological Joint Implants	II-30	Geron Inks Two Licensing Agreements with Revivicor.....	II-39
Scotland Plans to Build Center for Regenerative Medicine in Edinburgh	II-30	Geron Enters into a Licensing Agreement with P&G	II-39
Celmed BioSciences Merges with Kiadis.....	II-31	Roslin Institute, Geron, CXR Strike a Deal.....	II-39
Bayer Acquires Schering AG	II-31	Geron Signs a Licensing Agreement with Xcelsyz.....	II-40
Genentech Files IND Application with FDA.....	II-31	Geron Inks a Pact with Merix.....	II-40
National Stem Cell Holding and Azurel Merge.....	II-31	Agreement between HGSI and GlaxoSmithKline	II-40
StemCells and Stem Cell Therapeutics in Licensing Agreement.....	II-31	MacroPore Biosurgery Sells off Bioresorbable Thin Film Product Line	II-40
co.don Signs Distribution Agreement with Austrian Company	II-32	Jenapharm Divests Therapeutics Business	II-40
Olympus to Increase Investment in Olympus-Cytori, Inc.....	II-32	Celmed BioSciences Divests Celmed USA	II-41
Geron and University of Edinburgh in Collaboration for Development of hESCs	II-32	Schering Extends Research Facility in Japan.....	II-41
Ortho-McNeil Acquires ColBar LifeScience.....	II-32	Stem Cell Research Gets Approval in California.....	II-41
CCMB to Establish Research Center for Regenerative Medicine	II-33	Accentia Acquires Majority Stake in BioVest.....	II-41
Cambrex and Cytori Therapeutics in Strategic Alliance.....	II-33	DeveloGen Merges with Peptor.....	II-41
co.don Signs Distribution Agreement with XMEDICA	II-33	DeveloGen Partners with Evotec OAI.....	II-41
NCRM Signs MoU with Eye Hospital for Ocular Research.....	II-33	LifeCell Collaborates with NSCC	II-42
Theragen Receives Funding from Sanderling Ventures	II-34	LifeCell Corporation Accords with SHO	II-42
Musculoskeletal Transplant Foundation Signs Research and Investment Agreements with ProChon Biotech	II-34	Osiris Enters into a Licensing Agreement with JCR.....	II-42
Olympus and Cytori Therapeutics Establish Olympus-Cytori, Inc.....	II-34	TiGenix Inks a Pact with IQL.....	II-42
StemCo Biomedical is now Aldagen, Inc.....	II-35	BioVest International Signs an Agreement with BioE, Inc.....	II-42
Healthuniverse Establishes R&D Base in Singapore.....	II-35	PPL Therapeutics Divests Regenerative Medicine Business	II-43
BioMimetic Receives FDA Approval for GEM 21S®	II-35	Osiris Bags EU Patent for Matter Composition in Adult, Human MSC	II-43
Gambro and Nephrogen in Research Partnership.....	II-36	J-TEC and Nagoya University Develop Cell Culture System.....	II-43
UC-Berkley Bags US\$ 2.5 Million Grant from CIRM	II-36	Marubeni Takes a Minor Stake in GBS.....	II-43
MacroPore Biosurgery Receives US\$ 11 Million through Equity Placement.....	II-36	Tepha Develops New Biomaterials for Regenerative Medicine	II-43
World's third Largest Laboratory for Regenerative Medicine	II-37	Gunze Inaugurates Regenerative Medicine Research Facility	II-44
Ortec Forms a Joint Venture with HAPTO	II-37	Geron Corporation and Exeter Life Sciences Establish stART Licensing, Inc.....	II-44
Curis Extends Agreement with Genentech.....	II-37	Cambrex Establishes New Facility to Manufacture Cell Therapy	II-44
Curis Strikes a Deal with Genentech.....	II-37	6. Focus on Select Global Players.....	II-45
		BioVest International, Inc. (US).....	II-45
		Curis, Inc. (US)	II-45
		Cytori Therapeutics, Inc. (US)	II-46
		DeveloGen AG (Germany).....	II-46
		Forticell Bioscience, Inc. (US)	II-47
		Geron Corporation (US).....	II-47

CONTENTS

Human Genome Sciences, Inc. (US).....	II-48	IsoTis, Inc.	III-7
IsoTis, Inc. (US)	II-48	Osiris Therapeutics, Inc.	III-7
Kiadis Pharma B.V.	II-48	Revivicor, Inc.	III-7
LifeCell Corporation (US).....	II-49	Tepha Inc.	III-8
Osiris Therapeutics, Inc. (US).....	II-49	Other Key Players & Activities	III-8
Tepha Inc. (US).....	II-50	Technological Developments	III-10
TiGenix N.V. (Belgium)	II-50	Strategic Developments.....	III-13
7. Global Market Perspective	II-52	B. Market Analytics	III-23
<i>Table 1: World Recent Past, Current & Future Market Analysis for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region – US, Japan and Europe Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)</i>	II-52	<i>Table 5: US Recent Past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US\$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)</i>	III-23
<i>Table 2: World Long-term Projections for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region – US, Japan and Europe Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)</i>	II-52	<i>Table 6: US Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)</i>	III-23
<i>Table 3: World 8-Year Perspective for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan and Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)</i>	II-53	2. Japan	III-24
III. MARKET		A. Market Analysis	III-24
1. The United States	III-1	Market Potential	III-24
A. Market Analysis	III-1	Research Activity in Regenerative Medicine Field.....	III-24
Market Potential	III-1	More Companies Eye the Regenerative Medicine Potential.....	III-24
Regenerative Medicine in Bone and Joint Applications	III-1	Competition Heats up Behind Closed Doors	III-25
Regenerative Therapy – Best Fit for Joint Problems	III-1	Japanese Firms Need to Catch Up with US and European Competitors	III-25
Millions of American Patients Put their Hope in Stem Cell Research.....	III-2	Science Ministry Rolls Out Regenerative Medicine Project.....	III-25
<i>Table 4: Prevalence of Various Diseases in the US</i>	III-2	Regenerative Medicine Exempted from Ban on Human Cloning.....	III-26
US Witnesses Mixed Response for Government Support for hESC Research	III-3	Technological Developments	III-26
CBI's Human Tissue Products for Treating Liver Failure and Diabetes.....	III-3	Strategic Developments.....	III-27
Market for Liver and Pancreas Transplantation	III-4	Developments in Recent Past	III-27
Implantable Regenerative Products Take Over Sports Medicine	III-4	B. Market Analytics	III-28
Key Players	III-4	<i>Table 7: Japanese Recent Past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US\$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)</i>	III-28
BioVest International, Inc.	III-4	<i>Table 8: Japanese Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)</i>	III-29
Curis, Inc.	III-5	3. Europe	III-30
Cytori Therapeutics, Inc.....	III-5	A. Market Analysis	III-30
Geron Corporation.....	III-6	Germany.....	III-30
Human Genome Sciences, Inc.	III-6	Key Players.....	III-30
		co.don AG	III-30
		DeveloGen AG	III-30
		United Kingdom.....	III-31

CONTENTS

Belgium.....	III-31	4b. Asia-Pacific	III-39
Select Player.....	III-31	China.....	III-39
TiGenix N.V.....	III-31	Substantial Government Support.....	III-39
Strategic Developments.....	III-32	India.....	III-39
B. Market Analytics	III-36	CSIR- Leading the way in Regenerative	
<i>Table 9: European Recent Past, Current & Future</i>		Medicine Research.....	III-39
<i>Analysis for Regenerative Medicine Products for Bone</i>		High Growth Opportunities.....	III-39
<i>and Joint Applications – Annual Sales Figures in US\$</i>		Australia.....	III-40
<i>Million for Years 2003 through 2010 (includes</i>		Key Player.....	III-40
<i>corresponding Graph/Chart)</i>	III-36	Stem Cell Sciences.....	III-40
<i>Table 10: European Long-Term projections for</i>		South Korea.....	III-40
<i>Regenerative Medicine Products for Bone and Joint</i>		Malaysia.....	III-40
<i>Applications – Annual Sales Figures in US\$ Million for</i>		Singapore.....	III-41
<i>Years 2011 through 2015 (includes corresponding</i>		Strategic Developments.....	III-41
<i>Graph/Chart)</i>	III-36	4c. Rest of World	III-44
4. Review of Regenerative Medicine in Other		Argentina.....	III-44
Geographic Markets	III-37	Israel.....	III-44
4a. Canada	III-37	Select Major Players.....	III-44
University of Toronto – Spearheading Regenerative		Colbar R&D Ltd.....	III-44
Medicine Research.....	III-37	ProChon Biotech Ltd.....	III-44
Strategic Developments.....	III-37	South Africa.....	III-45
		Strategic Development.....	III-45

IV. COMPETITIVE LANDSCAPE